文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

术前免疫调节营养对胃肠道肿瘤手术结局影响的系统评价与Meta分析

The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Ann Surg · 2019-01-01

该系统评价与Meta分析纳入16项随机对照试验共1387例胃肠道肿瘤手术患者,评估术前口服或肠内免疫调节营养(IMN)对术后结局的影响。结果显示术前IMN可显著降低术后感染性并发症(OR 0.52,95%CI 0.38-0.71,P<0.0001)并缩短住院时间(加权均数差-1.57天,95%CI -2.48至-0.66,P=0.0007),但对非感染性并发症和死亡率无显著影响。结论推荐在胃肠道肿瘤手术患者常规实践中鼓励使用术前IMN。

要点

  • 术前IMN降低胃肠道肿瘤手术后感染性并发症风险(OR 0.52)。
  • 术前IMN缩短住院时间约1.57天,非感染性并发症和死亡率无显著改变。
  • 所有研究采用含ω-3脂肪酸、精氨酸和核苷酸的Impact配方。

核心结论

  • 术前免疫调节营养应被鼓励用于胃肠道肿瘤手术患者的常规实践。

研究设计与样本

  • 系统评价与Meta分析,检索Embase、Medline和Cochrane数据库2000至2018年前瞻性随机对照试验。
  • 纳入16项研究共1387例患者(IMN组715例,对照组672例)。
  • 干预为术前口服或肠内免疫调节营养,对照为等热量等氮喂养或正常饮食。

主要发现

  • 术前IMN降低感染性并发症(OR 0.52,95%CI 0.38-0.71,P<0.0001,I=16%,n=1387)。
  • 术前IMN缩短住院时间(加权均数差-1.57天,95%CI -2.48至-0.66,P=0.0007,I=34%,n=995)。
  • 非感染性并发症无显著差异(OR 0.98,95%CI 0.73-1.33,P=0.91,I=0%,n=1303)。
  • 死亡率无显著差异(OR 0.55,95%CI 0.18-1.68,P=0.29,I=0%,n=955)。

关键数值与推荐

  • 所有研究中治疗组使用的营养配方均为Impact(Novartis/Nestlé),含ω-3脂肪酸、精氨酸和核苷酸。
  • 研究覆盖混合胃肠道肿瘤手术(6项)、结直肠癌手术(4项)、胰腺手术(2项)、胃癌手术(2项)、肝癌和食管癌手术各1项。

临床怎么用

  • 对胃肠道肿瘤手术患者,可考虑术前给予含ω-3脂肪酸、精氨酸和核苷酸的免疫调节营养以降低感染性并发症。
  • 术前IMN可能缩短住院时间,但需结合患者具体情况评估。

局限性

  • 纳入研究人群涵盖不同胃肠道肿瘤手术类型,异质性可能影响结果解释。
  • 所有研究使用同一品牌配方,结果外推至其他配方需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the influence of preoperative immune modulating nutrition (IMN) on postoperative outcomes in patients undergoing surgery for gastrointestinal cancer. BACKGROUND: Although studies have shown that perioperative IMN may reduce postoperative infectious complications, many of these have included patients with benign and malignant disease, and the optimal timing of such an intervention is not clear. METHODS: The Embase, Medline, and Cochrane databases were searched from 2000 to 2018, for prospective randomized controlled trials evaluating preoperative oral or enteral IMN in patients undergoing surgery for gastrointestinal cancer. The primary endpoint was the development of postoperative infectious complications. Secondary endpoints included postoperative noninfectious complications, length of stay, and up to 30-day mortality. The analysis was performed using RevMan v5.3 software. RESULTS: Sixteen studies reporting on 1387 patients (715 IMN group, 672 control group) were included. Six of the included studies reported on a mixed population of patients undergoing all gastrointestinal cancer surgery. Of the remaining, 4 investigated IMN in colorectal cancer surgery, 2 in pancreatic surgery, and another 2 in patients undergoing surgery for gastric cancer. There was 1 study each on liver and esophageal cancer. The formulation of nutrition used in all studies in the treated patients was Impact (Novartis/Nestlé), which contains ω-3 fatty acids, arginine, and nucleotides. Preoperative IMN in patients undergoing surgery for gastrointestinal cancer reduced infectious complications [odds ratio (OR) 0.52, 95% confidence interval (CI) 0.38-0.71, P < 0.0001, I = 16%, n = 1387] and length of hospital stay (weighted mean difference -1.57 days, 95% CI -2.48 to -0.66, P = 0.0007, I = 34%, n = 995) when compared with control (isocaloric isonitrogeneous feed or normal diet). It, however, did not affect noninfectious complications (OR 0.98, 95% CI 0.73-1.33, P = 0.91, I = 0%, n = 1303) or mortality (OR 0.55, 95% CI 0.18-1.68, P = 0.29, I = 0%, n = 955). CONCLUSION: Given the significant impact on infectious complications and a tendency to shorten length of stay, preoperative IMN should be encouraged in routine practice in patients undergoing surgery for gastrointestinal cancer.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Adiamah A, Skořepa P, Weimann A, et al. The Impact of Preoperative Immune Modulating Nutrition on Outcomes in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2019. PMID: 30817349. doi:10.1097/SLA.0000000000003256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。